Form 8-K - Current report:
SEC Accession No. 0001193125-25-015901
Filing Date
2025-01-29
Accepted
2025-01-29 17:25:42
Documents
17
Period of Report
2025-01-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d197264d8k.htm   iXBRL 8-K 29650
2 EX-1.1 d197264dex11.htm EX-1.1 290771
3 EX-4.1 d197264dex41.htm EX-4.1 66715
4 EX-5.1 d197264dex51.htm EX-5.1 8624
8 GRAPHIC g197264g0129122632844.jpg GRAPHIC 2608
  Complete submission text file 0001193125-25-015901.txt   622893

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA etnb-20250128.xsd EX-101.SCH 2844
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20250128_lab.xml EX-101.LAB 17994
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20250128_pre.xml EX-101.PRE 11257
19 EXTRACTED XBRL INSTANCE DOCUMENT d197264d8k_htm.xml XML 3627
Mailing Address 655 MONTGOMERY STREET SUITE 1500 SAN FRANCISCO CA 94111
Business Address 655 MONTGOMERY STREET SUITE 1500 SAN FRANCISCO CA 94111 (415) 432-9270
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39122 | Film No.: 25570409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)